Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest Update

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 21,980,000 shares, a growth of 12.7% from the October 15th total of 19,500,000 shares. Based on an average daily trading volume, of 2,210,000 shares, the short-interest ratio is presently 9.9 days.

Analyst Ratings Changes

Separately, Citigroup dropped their target price on Lexicon Pharmaceuticals from $8.00 to $5.00 in a research report on Friday, August 4th.

Insider Buying and Selling

In other Lexicon Pharmaceuticals news, Director Raymond Debbane bought 148,820 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were acquired at an average cost of $1.03 per share, for a total transaction of $153,284.60. Following the purchase, the director now directly owns 1,340,847 shares of the company’s stock, valued at $1,381,072.41. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have acquired 677,126 shares of company stock worth $756,653. Corporate insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several institutional investors have recently bought and sold shares of LXRX. Artal Group S.A. raised its position in shares of Lexicon Pharmaceuticals by 30.9% during the 2nd quarter. Artal Group S.A. now owns 117,553,284 shares of the biopharmaceutical company’s stock valued at $269,197,000 after buying an additional 27,775,050 shares in the last quarter. BVF Inc. IL raised its position in Lexicon Pharmaceuticals by 23.8% during the second quarter. BVF Inc. IL now owns 19,995,332 shares of the biopharmaceutical company’s stock valued at $45,789,000 after purchasing an additional 3,846,153 shares during the period. BlackRock Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 12.8% in the 2nd quarter. BlackRock Inc. now owns 6,379,186 shares of the biopharmaceutical company’s stock valued at $14,608,000 after purchasing an additional 722,259 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Lexicon Pharmaceuticals by 34.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,256,288 shares of the biopharmaceutical company’s stock worth $12,614,000 after purchasing an additional 1,334,318 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Lexicon Pharmaceuticals by 0.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,305,991 shares of the biopharmaceutical company’s stock valued at $8,034,000 after purchasing an additional 29,193 shares during the last quarter.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.12 on Wednesday. The stock has a market cap of $274.32 million, a PE ratio of -1.47 and a beta of 1.16. The company’s fifty day moving average is $1.21 and its 200 day moving average is $1.94. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.79. The company has a quick ratio of 6.91, a current ratio of 6.92 and a debt-to-equity ratio of 0.71.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.49 million. Lexicon Pharmaceuticals had a negative net margin of 29,728.25% and a negative return on equity of 118.90%. Research analysts anticipate that Lexicon Pharmaceuticals will post -0.81 earnings per share for the current year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.